NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
47.23
-0.43 (-0.90%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close47.66
Open47.03
Bid0.00 x 0
Ask0.00 x 0
Day's Range46.92 - 47.46
52 Week Range36.39 - 58.37
Volume2,587,375
Avg. Volume1,549,907
Market Cap114.052B
Beta0.82
PE Ratio (TTM)18.61
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (2.61%)
Ex-Dividend Date2018-03-23
1y Target EstN/A
Trade prices are not sourced from all markets
  • Analysts’ Recommendations for Novartis on April 17
    Market Realist4 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Alcon
    Market Realist4 days ago

    Novartis’s 1Q18 Estimates: Expectations for Alcon

    Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist5 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • Novo Nordisk Stock Performance in 1Q18
    Market Realist11 days ago

    Novo Nordisk Stock Performance in 1Q18

    Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.

  • Novo Nordisk Obtains Licence for Sickle Cell Disease Program
    Zacks15 days ago

    Novo Nordisk Obtains Licence for Sickle Cell Disease Program

    Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

  • Reuters17 days ago

    Novo Nordisk buys blood drug licence to boost anaemic biopharma business

    Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.

  • These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
    Investor's Business Dailylast month

    These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

    A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.

  • 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
    Insider Monkeylast month

    30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets

    The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]

  • Reuterslast month

    Drugmaker Novo Nordisk looks to former oil boss to energise M&A

    Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.

  • Novo Nordisk Poised on Strong Pipeline Amid Competition
    Zackslast month

    Novo Nordisk Poised on Strong Pipeline Amid Competition

    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.

  • Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
    Zackslast month

    Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

    Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

  • Novartis’s Innovative Medicines Business in 4Q17
    Market Realistlast month

    Novartis’s Innovative Medicines Business in 4Q17

    How Novartis Fared in 4Q17

  • How Novartis’s Business Segments Performed in 4Q17
    Market Realistlast month

    How Novartis’s Business Segments Performed in 4Q17

    How Novartis Fared in 4Q17

  • How AstraZeneca’s Other Products Portfolio Performed in 4Q17
    Market Realistlast month

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    What's Driving AstraZeneca’s Valuation in March 2018?

  • How AstraZeneca’s Revenues Trended in 4Q17
    Market Realistlast month

    How AstraZeneca’s Revenues Trended in 4Q17

    What's Driving AstraZeneca’s Valuation in March 2018?

  • Novo Nordisk Focuses on Expanding Semaglutide’s Label
    Market Realistlast month

    Novo Nordisk Focuses on Expanding Semaglutide’s Label

    Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.

  • Label Expansion May Boost Xultophy’s Sales in 2018
    Market Realistlast month

    Label Expansion May Boost Xultophy’s Sales in 2018

    What Are Novo Nordisk's Key Growth Drivers for 2018?

  • Saxenda May Continue to Lead in the Diabetes Segment in 2018
    Market Realistlast month

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.

  • Xultophy May Prove a Strong Growth Driver for NVO in 2018
    Market Realistlast month

    Xultophy May Prove a Strong Growth Driver for NVO in 2018

    Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017, a 252% YoY (year-over-year) rise on a reported basis and a 255% YoY rise in local currencies. The uptake of Xultophy, a combination of Tresiba and Victoza, was mainly driven by increasing demand in European and North American markets. Xultophy secured approval from the FDA on November 21, 2016, as a once-daily injectable adjunct therapy for type 2 diabetes patients who don’t respond adequately to a daily intake of 50 units of basal insulin or up to 1.8 mg of Victoza (liraglutide).

  • Novo Nordisk Has Developed a Portfolio of New-Generation Insulins
    Market Realistlast month

    Novo Nordisk Has Developed a Portfolio of New-Generation Insulins

    Novo Nordisk (NVO) has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among GPs (general practitioner) and PCPs (primary care physician). Patients suffering from type 1 diabetes are generally treated by endocrinologists, who focus on factors such as low intra-patient glycemic variability, a flat and stable drug profile, fewer hypoglycemia events, patient convenience, and confidence in the product while prescribing drugs. Because GPs and PCPs don’t focus on glycemic variability and hypoglycemia events, Novo Nordisk’s efforts to raise awareness are expected to drive the adoption of Tresiba in the type 2 diabetes patient population.

  • Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits
    Market Realist2 months ago

    Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

    Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18. In 4Q17, the company also submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for updating Tresiba’s label to reflect hypoglycemia data from the DEVOTE trial. Novo Nordisk is anticipating a readout of the results from its trial comparing Tresiba to insulin glargine U300 in 4Q18.

  • Tresiba Emerged as a Blockbuster Therapy in 2017
    Market Realist2 months ago

    Tresiba Emerged as a Blockbuster Therapy in 2017

    In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status. The drug has witnessed rapid uptake in markets in which it has par access compared to competing products, such as insulin glargine U100. In the United States, Novo Nordisk managed to attain a 34% share of the total basal insulin market by volume as of January 2018.

  • Will NVO Continue to Lead the Global Insulin Market in 2018?
    Market Realist2 months ago

    Will NVO Continue to Lead the Global Insulin Market in 2018?

    Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies. The company considers affordability to be the key commercial aspect of its human insulin portfolio, which mainly caters to diabetes patients with lower purchasing power. Novo Nordisk believes that high familiarity owing to long-term presence in the market is a major competitive advantage for its modern insulin portfolio.

  • Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care
    Market Realist2 months ago

    Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care

    What Are Novo Nordisk's Key Growth Drivers for 2018?

  • Diabetes Care Segment Continues to Drive Growth for NVO in 2018
    Market Realist2 months ago

    Diabetes Care Segment Continues to Drive Growth for NVO in 2018

    According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes. Of these, 11.2 million patients are estimated to be treated with the company’s human insulin products, 12.5 million with its modern insulin products, 0.9 million with its new-generation insulin products, and the remaining 1.4 million with its glucagon-like peptide 1 (or GLP-1) products.